$GILD Recent Headlines When it comes to stocks, play

New Post Public Reply Private Reply Replies (0) Message Board

Feb 19, 2014 at 12:39 PM

$GILD Recent Headlines

When it comes to stocks, play follow the leader 3:54 p.m. Feb. 13, 2014 - The Trading Deck
3D Systems down on weak outlook, CVS quits cigarettes 4:16 p.m. Feb. 5, 2014 - Saumya Vaishampayan
Time Warner, Twitter, Walt Disney are stocks to watch 5:48 a.m. Feb. 5, 2014 - Sue Chang
Tableau Software, Myriad shares rally after earnings 6:02 p.m. Feb. 4, 2014 - Wallace Witkowski
Gilead does the expected by beating earnings and sales forecasts 5:13 p.m. Feb. 4, 2014 - blogs.marketwatch.com
Updates, advisories and surprises 4:31 p.m. Feb. 4, 2014 - MarketWatch
Gilead beats sales, earnings forecasts 4:27 p.m. Feb. 4, 2014 - Russ Britt
Gilead sales forecast beats $10.93B analyst view 4:18 p.m. Feb. 4, 2014 - Russ Britt
Gilead forecasts 2014 sales of $11.3B to $11.5B 4:17 p.m. Feb. 4, 2014 - Russ Britt
Gilead Q4 revs of $3.12B beats $2.85B estimate 4:14 p.m. Feb. 4, 2014 - Russ Britt
Gilead Q4 revs. are $3.12B vs 2012's $2.59B 4:13 p.m. Feb. 4, 2014 - Russ Britt
Gilead Q4 net of 55 cents beats views by 5 cents 4:12 p.m. Feb. 4, 2014 - Russ Britt
Gilead Q4 net is 55 cents vs. 2012's 50 cents 4:11 p.m. Feb. 4, 2014 - Russ Britt
Analyst upgrades Gilead, says biotech is 'too good not to own' 2:06 p.m. Feb. 4, 2014 - blogs.marketwatch.com
Happy B-day, Facebook! Enjoy the gift of global market turmoil 7:10 a.m. Feb. 4, 2014 - blogs.marketwatch.com
Yum Brands, Take-Two, CME are stocks to watch Tuesday 5:30 a.m. Feb. 4, 2014 - Sue Chang
More positive tests for hep C drug boost AbbVie and Enanta shares 10:52 a.m. Jan. 31, 2014 - blogs.marketwatch.com
Cash ain’t trash 1:55 p.m. Jan. 28, 2014 - The Trading Deck
Beware the dead-cat bounce 1:24 p.m. Jan. 28, 2014 - Michael Ashbaugh
Beware the dead-cat bounce 1:06 p.m. Jan. 28, 2014 - Michael Ashbaugh

Biotech Stock Roundup: Regeneron's Eylea Impresses, Gilead Files for Next HCV Drug - Analyst Blog 9:27 a.m. Today - Zacks.com
Gilead Sciences Inc (GILD): Today's Featured Drugs Winner 5:00 p.m. Feb. 18, 2014 - TheStreet.com
Biotech Remains on Fast Track 11:00 a.m. Feb. 18, 2014 - RealMoney.com
Gilead Sciences: A Great Buy Despite Competition From AbbVie 10:37 a.m. Feb. 18, 2014 - Seeking Alpha
3 Healthcare Stocks That Look Ripe to Rally 6:04 a.m. Feb. 18, 2014 - InvestorPlace.com
3 Stocks Pulling The Drugs Industry Downward 12:03 p.m. Feb. 14, 2014 - TheStreet.com
How To Maximize Potential Return While Protecting Against A Severe Correction 10:50 a.m. Feb. 13, 2014 - Seeking Alpha
Top Pharma and Biotech Stocks to Buy From Key Investor Conference 9:50 a.m. Feb. 13, 2014 - 247WallSt.com
Gilead Sciences: 5 Different Insiders Have Sold Shares This Year 5:00 a.m. Feb. 13, 2014 - Seeking Alpha
Gilead a Given for Hepatitis C Favorite 10:22 a.m. Feb. 12, 2014 - Barrons.com
Stock Market News for February 12, 2014 - Market News 10:06 a.m. Feb. 12, 2014 - Zacks.com
Biotech Stock Roundup: Gilead's Sovaldi Impresses, EU Nod for Biogen's Tecfidera - Analyst Blog 8:27 a.m. Feb. 12, 2014 - Zacks.com
Short Sellers Shy Away From Biotechs 6:04 a.m. Feb. 12, 2014 - 247WallSt.com
Buy GILD Now Before Its Next Breakout 7:16 p.m. Feb. 11, 2014 - InvestorPlace.com
Gilead Sciences Inc (GILD): Today's Featured Drugs Winner 5:00 p.m. Feb. 11, 2014 - TheStreet.com
Gilead Seeks U.S. Approval - Analyst Blog 4:00 p.m. Feb. 11, 2014 - Zacks.com
Stock Market News for February 11, 2014 - Market News 10:06 a.m. Feb. 11, 2014 - Zacks.com
Gilead +2.8% on positive talk, Sovaldi would make numbers look even better 3:59 p.m. Feb. 10, 2014 - Seeking Alpha
Gilead Going to $90, or $110 2:37 p.m. Feb. 10, 2014 - 247WallSt.com
Three ETFs To Buy On The Pullback (PJP, SKYY, SPY) 8:13 a.m. Feb. 10, 2014 - Benzinga.com

CURx Pharmaceuticals Announces License Agreement with Gilead Sciences 8:00 a.m. Today - PR Newswire - PRF
Galectin Therapeutics Leaps Ahead with SBH Sciences Partnership 11:02 a.m. Feb. 13, 2014 - ACCESSWIRE
Brazilian Pharmaceutical Market 2014-2024 10:03 a.m. Feb. 12, 2014 - PR Newswire - PRF
Gilead Sciences to Present at Two Upcoming Investor Conferences 5:00 p.m. Feb. 10, 2014 - BusinessWire - BZX
Gilead Files for U.S. Approval of Ledipasvir/Sofosbuvir Fixed-Dose Combination Tablet for Genotype 1 Hepatitis C 4:05 p.m. Feb. 10, 2014 - BusinessWire - BZX
Gilead Sciences Announces Fourth Quarter and Full Year 2013 Financial Results 4:05 p.m. Feb. 4, 2014 - BusinessWire - BZX
Critical Alerts For Procter and Gamble, Randgold Resources, Cerner, Gilead Sciences, and Walter Energy Released By InvestorsObserver 9:31 a.m. Feb. 4, 2014 - PR Newswire - PRF
Mylan Named as Gilead's Exclusive Branded Medicines Business Partner for India 12:30 a.m. Jan. 31, 2014 - PR Newswire - PRF
Gilead Sciences to Release Fourth Quarter and Year End 2013 Financial Results on Tuesday, February 4, 2014 5:00 p.m. Jan. 28, 2014 - BusinessWire - BZX
Gilead Announces Executive Promotions 5:00 p.m. Jan. 27, 2014 - BusinessWire - BZX
European Commission Grants Marketing Authorization for Gilead’s Sovaldi® (Sofosbuvir) for the Treatment of Chronic Hepatitis C Infection 9:09 a.m. Jan. 17, 2014 - BusinessWire - BZX
Acceptance of NDA for Review, Acquisitions of Development Rights, Earnings Release Schedulesm and New Leaders - Research Report on Gilead, Lilly, Allergan, Incyte, and Varian Medical Systems 8:00 a.m. Jan. 16, 2014 - PR Newswire - PRF
U.S. FDA Accepts New Drug Application for Gilead’s Idelalisib for the Treatment of Refractory Indolent Non-Hodgkin’s Lymphoma 8:30 a.m. Jan. 13, 2014 - BusinessWire - BZX
Biotoscana agrees to acquire United Medical to expand commercial presence in Brazil and create a leading regional specialty pharmaceutical company in South America 1:15 a.m. Jan. 13, 2014 - BusinessWire - BZX
Gilead Sciences to Present at the 32nd Annual JPMorgan Healthcare Conference on Monday, January 13 5:00 p.m. Jan. 10, 2014 - BusinessWire - BZX
Retirement Announcements, Stock Price Movements, and Scheduled Conferences Presentations - Research Report on Gilead, Aegerion, Celldex, Alnylam, and Ironwood 8:00 a.m. Jan. 9, 2014 - PR Newswire
Stock Price Movements, Conference Presentation Schedules, and Expanded Sharing of Clinical Data - Research Report on Gilead, Express Scripts, Sanofi, Agilent, and Kythera Biopharma 8:00 a.m. Jan. 8, 2014 - PR Newswire
Galectin Therapeutics Receives Patent for Combination Treatment for Liver Fibrosis 12:17 p.m. Jan. 7, 2014 - ACCESSWIRE
Notable Buzzers: Apple Inc, Stereotaxis Inc, Tiger Oil and Energy Inc, Gilead Sciences Inc 11:00 a.m. Jan. 7, 2014 - ACCESSWIRE
Gilead Sciences' Kevin Young CBE, Executive Vice President, Commercial Operations, to Retire 4:29 p.m. Jan. 6, 2014 - BusinessWire

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Likang's Bold Move: Cancer Immunotherapy at AD Summit

Cancer Care Takes Center Stage Kicking off with a bang in Abu Dhabi, Likang Life Sciences has made a splash in the world of personalized cancer immunotherapy. The Abu Dhabi Future Health Summit 2026 served as the backdrop for this bold move, lighting up discussions with their AI-enabled innovations. Likang's showing at the Summit wasn't just another walk in the park—it...

Ping An's Bold Green Moves Ahead of APEC 2026

Ping An's Pitch for Green: Talking the Talk and Walking the Walk? Well, here's something cooking in Shenzhen at the Ping An Finance Center—an international seminar championing green development initiatives. It's all buzz around Ping An Insurance (HKEX: 2318; SSE: 601318) flexing its green muscle, orchestrating conversations right before APEC 2026. Talk about timing....

ST Engineering iDirect, MBSat Forge Middle East Satellite Hub

Satellite Services Take Off in the Middle East Never thought the day would come where the Middle East is on the threshold of leapfrogging satellite tech, but here we are. ST Engineering iDirect just locked arms with MBSat—yep, that's part of the Mohammed Al Barwani Group—to birth a next-gen satellite connectivity service hub in Oman and across surrounding areas....

Innovent's IBI3001 Shows Promise in Phase 1 Trials

Pioneering Path with IBI3001 at ESMO 2026 Navigating through the crowded landscape of oncology trials, Innovent Biologics recently rolled out some riveting Phase 1 clinical data for their new darling, IBI3001. Top brass from Innovent took to the European Society for Medical Oncology (ESMO) Congress stage to lay bare their findings. Obviously, when you're presenting a...

Johnson & Johnson's JNJ-6143 Shines in Prostate Cancer Study

Prostate Cancer's Persistent Challenge No one in the healthcare game needs the reminder: prostate cancer is no walk in the park, especially for those grappling with advanced stages. Now picture this—you're on your sixth treatment, and the cloud is not lifting. It's a battle that never ends, with traditional therapies sometimes barely holding the line. JNJ-6143's New...

Innovent's IBI354: New Data Spurs Hope for HER2+ BC

Innovent Lauds HER2 ADC's Moment at ESMO 2026 Alright, chin up, investors. At the 2026 ESMO Congress, Innovent's throwing down some promising Phase 2 data for their brainchild, IBI354. You hear that name and it's like hearing about a rock star in the making in the oncology world. The potential here isn’t just talk—it's a loud, resounding call for attention. Their...

CapCut's Role in AI-Assisted Small Biz Marketing

In today's fast-paced digital world, small businesses lament the constant hustle to stay relevant online. This juggling act with limited resources often makes effective marketing feel like a high-wire circus performance. Enter AI tools, promising to lighten the load, and CapCut stands out as a game-changer. AI Tools Revolutionizing Small Business Marketing Amid growing...

What to Expect: Your First Therapy Session Insights

Starting With the Unknown: The Therapy Journey Begins Rolling into that first therapy session can feel like walking into a mystery with no clues. You're not alone if it stirs up some nerves—most folks feel the same, especially when it's your first rodeo in mental health support. That's where Cody Luke and David Spencer of Luke and Spencer Behavioral Health, based out in...

Kelun-Biotech's Sacituzumab Tirumotecan Shows Promise in NSCLC

Kelun-Biotech's Recent Breakthrough Grab your coffee, and let's chat about something that might just change the lung cancer treatment game: Kelun-Biotech's sacituzumab tirumotecan, or sac-TMT, showing some serious promise in a Phase III trial. With numbers that could make any investor sit up a little straighter, this study has turned heads at the European Society for...

Swanson Nexus Pro Launch: Boost for Dietitians

By Lucas Young Updated Oct 24, 2026 Category News Views 195

Swanson Enters the Education Arena for Nutritionists Swanson Vitamins is mixing things up again! This time, they're launching something called Swanson Vitamins Nexus Pro, aimed squarely at the registered dietitians and licensed nutritionists crowd. Starting out as the place to grab your basic vitamins, Swanson's not resting on their supplement laurels. No, siree. They've...